187 related articles for article (PubMed ID: 32238663)
1. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
[TBL] [Abstract][Full Text] [Related]
2. Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy.
Yonishi H; Namba-Hamano T; Hamano T; Hotta M; Nakamura J; Sakai S; Minami S; Yamamoto T; Takahashi A; Kobayashi W; Maeda I; Hidaka Y; Takabatake Y; Sakai N; Isaka Y
Nephrol Dial Transplant; 2021 Dec; 37(1):53-62. PubMed ID: 33367839
[TBL] [Abstract][Full Text] [Related]
3. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
4. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
5. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
7. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
8. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
Braun F; Abed A; Sellung D; Rogg M; Woidy M; Eikrem O; Wanner N; Gambardella J; Laufer SD; Haas F; Wong MN; Dumoulin B; Rischke P; Mühlig A; Sachs W; von Cossel K; Schulz K; Muschol N; Gersting SW; Muntau AC; Kretz O; Hahn O; Rinschen MM; Mauer M; Bork T; Grahammer F; Liang W; Eierhoff T; Römer W; Hansen A; Meyer-Schwesinger C; Iaccarino G; Tøndel C; Marti HP; Najafian B; Puelles VG; Schell C; Huber TB
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37014703
[TBL] [Abstract][Full Text] [Related]
10. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Sakuraba H; Togawa T; Tsukimura T; Kato H
Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
[TBL] [Abstract][Full Text] [Related]
11. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Chen Z; Yin B; Jiao J; Ye T
BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
[TBL] [Abstract][Full Text] [Related]
12. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
CEN Case Rep; 2023 Dec; ():. PubMed ID: 38135868
[TBL] [Abstract][Full Text] [Related]
13. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
14. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
16. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.
Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS
Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114
[TBL] [Abstract][Full Text] [Related]
17. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
18. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
F1000Res; 2021; 10():841. PubMed ID: 34745562
[TBL] [Abstract][Full Text] [Related]
19. Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS.
Byeon SK; Kim JY; Lee JS; Moon MH
Anal Bioanal Chem; 2016 Mar; 408(9):2265-74. PubMed ID: 26873218
[TBL] [Abstract][Full Text] [Related]
20. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
